Program to enrich translation and multimodal research in Alzheimers disease and related dementias

摘要 这是T32培训补助金申请的重新提交，题为“丰富翻译和 阿尔茨海默病和相关痴呆症的多模式研究（ADRD的PET和MR）。主要目标是 提供丰富的2年博士后培训经验，在多模态神经成像，重点是：[1] 衰老和神经退化生物学; [2]数据科学，计算生物学，统计学，数学， 工程，生物物理学;和[3]药物发现和药物开发学科。 T32计划背后的理由是多方面的。首先，必须向受训人员提供 利用现有技术优势的工具，推动新兴技术的发展， 确定推进阿尔茨海默病（AD）治疗发展的创新途径。其意义 许多过去的AD试验失败和最近几次试验提供的新希望强调了培训。 其次，神经影像学扩大了我们对生活中与年龄和疾病相关的大脑变化的认识。 并被证明是发现和开发新药的有用工具。神经影像 在试验研究设计和药物的中期评估中， 性能第三，AD和AD相关痴呆的PET和MRI确保了多学科团队的培训 科学 这个T32将支持4个博士后培训名额，由博士，医学博士和/或医学博士/博士申请人填补。 将有20名高级教师和7名初级教师，主要隶属于MGH Martinos中心， 生物医学成像和马萨诸塞州阿尔茨海默病研究中心。双方的董事 中心是T32教师。这些中心大力支持多样性和包容性。我们的目标是招募女性 和代表性不足的少数民族（URM）进入4个职位中的3个，以帮助解决对多元化劳动力的需求 和URM参与AD相关研究。培训包括负责任地开展研究， 道德和职业发展。 每名受训人员将与一名初级导师、一名二级导师和一名初级教师导师相匹配。这 将有助于确保在主要和次要重点领域提供强有力的指导，并促进团队建设， 反馈所有学员将担任暑期培训项目的导师。对T32计划的评估将 包括年度外部咨询委员会会议审查（哈佛医学部以外所有成员 一年两次的内部指导委员会会议;以及每季度对受训人员进行评价。学员将 在严格的研究实践，多样化的团队科学和指导方面获得经验，并将很好地 定位在T32培训期结束时，在AD相关研究中寻求独立资金。

Abstract This is the resubmission of a T32 training grant application entitled “Program to enrich translation and multimodal research in Alzheimer’s disease and related dementias (PET&MR in ADRD)”. The main goal is to provide a rich 2-year postdoctoral training experience in multimodal neuroimaging that focuses on: [1] the biology of aging and neurodegeneration; [2] data sciences, computational biology, statistics, mathematics, engineering, biophysics; and [3] drug discovery and drug development disciplines. The rationale behind this T32 program is multi-faceted. First, it is essential to provide trainees with the tools to leverage strengths of existing technologies, advance development of emerging technologies, and identify innovative paths for advancing Alzheimer’s disease (AD) therapy development. The significance of this training is underscored by many past AD trial failures and renewed promise offered by a few recent trials. Second, neuroimaging has expanded our knowledge of age- and disease-related brain changes in living humans and proven to be a useful tool in the discovery and development of new drugs. Neuroimaging measures are often considered as eligibility criteria in trial study designs and for interim assessment of drug performance. Third, PET and MRI in AD and AD-related dementias ensures training in multidisciplinary team science. This T32 will support 4 postdoctoral training slots to be filled by PhD, MD, and/or MD/PhD applicants. There will be 20 senior faculty and 7 junior faculty, largely affiliated with the MGH Martinos Center for Biomedical Imaging and the Massachusetts Alzheimer’s Disease Research Center. The Directors of both centers are T32 faculty. These centers strongly support diversity and inclusion. Our goal is to recruit women and underrepresented minorities (URM) into 3 of the 4 slots to help address the need for a diverse workforce and URM participation in AD-related research. Training includes the responsible conduct of research and ethics and career development. Each trainee will be matched with a primary mentor, secondary mentor, and a junior faculty mentor. This will help to ensure strong mentorship in primary and secondary focus areas and facilitate team building and feedback. All trainees will serve as mentors in summer training programs. Evaluation of the T32 program will include an annual External Advisory Committee meeting review (all members external to Harvard Medical School), biannual Internal Steering Committee meetings; and quarterly trainee evaluations. The trainees will gain experience in rigorous research practices, diverse team science, and mentoring and will be well positioned to pursue independent funding in AD-related research at the end of the T32 training period.